AGL 37.89 Decreased By ▼ -1.69 (-4.27%)
AIRLINK 126.00 Decreased By ▼ -5.22 (-3.98%)
BOP 6.83 Increased By ▲ 0.02 (0.29%)
CNERGY 4.45 Decreased By ▼ -0.26 (-5.52%)
DCL 7.89 Decreased By ▼ -0.55 (-6.52%)
DFML 37.32 Decreased By ▼ -4.15 (-10.01%)
DGKC 77.50 Decreased By ▼ -4.59 (-5.59%)
FCCL 30.60 Decreased By ▼ -2.50 (-7.55%)
FFBL 69.02 Decreased By ▼ -3.85 (-5.28%)
FFL 11.89 Decreased By ▼ -0.37 (-3.02%)
HUBC 105.50 Decreased By ▼ -5.24 (-4.73%)
HUMNL 13.50 Decreased By ▼ -1.01 (-6.96%)
KEL 4.67 Decreased By ▼ -0.52 (-10.02%)
KOSM 7.28 Decreased By ▼ -0.33 (-4.34%)
MLCF 36.60 Decreased By ▼ -2.30 (-5.91%)
NBP 65.30 Increased By ▲ 1.29 (2.02%)
OGDC 181.00 Decreased By ▼ -11.82 (-6.13%)
PAEL 24.58 Decreased By ▼ -1.10 (-4.28%)
PIBTL 7.15 Decreased By ▼ -0.19 (-2.59%)
PPL 144.00 Decreased By ▼ -10.07 (-6.54%)
PRL 24.40 Decreased By ▼ -1.43 (-5.54%)
PTC 16.40 Decreased By ▼ -1.41 (-7.92%)
SEARL 78.61 Decreased By ▼ -3.69 (-4.48%)
TELE 7.20 Decreased By ▼ -0.56 (-7.22%)
TOMCL 32.01 Decreased By ▼ -1.45 (-4.33%)
TPLP 8.15 Decreased By ▼ -0.34 (-4%)
TREET 16.10 Decreased By ▼ -0.52 (-3.13%)
TRG 54.89 Decreased By ▼ -2.51 (-4.37%)
UNITY 27.50 Decreased By ▼ -0.01 (-0.04%)
WTL 1.29 Decreased By ▼ -0.08 (-5.84%)
BR100 10,116 Decreased By -388.7 (-3.7%)
BR30 29,567 Decreased By -1659.1 (-5.31%)
KSE100 94,574 Decreased By -3505.6 (-3.57%)
KSE30 29,445 Decreased By -1113.9 (-3.65%)

Bangladesh's leading drug maker Beximco Pharmaceuticals Limited (BPL) said on Saturday it has raised 6.5 million pounds through the issue of 8,175,750 further global depository receipts (GDRs) on the London Stock Exchange, each representing one ordinary share of 10 taka each at an issue price of 80 pence per GDR.
The newly issued GDRs were admitted for trading on June 1 on the Alternative Investment Market (AIM) of the London Stock Exchange, a BPL statement said.
"We have been delighted by the interest in Beximco from international investors since the company's IPO in London last year and we are grateful to them for their continuing support in this fundraising as we develop the infrastructure of our business and invest in its growth," said Nazmul Hassan, Chief Executive Officer of Beximco Pharmaceuticals said in the statement.

Copyright Reuters, 2006

Comments

Comments are closed.